Abstract Number: L09 • ACR Convergence 2020
A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)
Background/Purpose: There is a high unmet need for systemic sclerosis (SSc) treatments. Ziritaxestat (ziri; GLPG1690) is an autotaxin inhibitor with a novel mechanism of action.…Abstract Number: L10 • ACR Convergence 2020
Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734
Background/Purpose: Plasmacytoid dendritic cells (pDCs) secrete large amounts of type I interferon (IFN) and other cytokines upon activation. pDCs migrate to sites of active disease…Abstract Number: 0946 • ACR Convergence 2020
ENPP1 Regulates UV Light Triggered Type I Interferon Response in the Skin
Background/Purpose: Systemic lupus erythematosus (SLE) patients have a prominent type I interferon (IFN-I) signature in both the lesional and non-lesional skin. We recently showed that…Abstract Number: 0956 • ACR Convergence 2020
An IL-18-Containing Five-Gene Signature Distinguishes Histologically Identical Dermatomyositis and Lupus Erythematosus Skin Lesions
Background/Purpose: Skin lesions in dermatomyositis (DM) patients are common, frequently refractory, and have prognostic significance. Histologically, DM lesions appear similar to cutaneous lupus erythematosus (CLE)…Abstract Number: 1172 • ACR Convergence 2020
Cardiovascular involvement as a clue for diagnosis of Juvenile Systemic Sclerosis sine scleroderma
Background/Purpose: Juvenile Systemic Sclerosis (JSSc) is a rare condition in childhood and its variety with no skin involvement, systemic sclerosis sine scleroderma (JSSSS) is anecdotal…Abstract Number: 1373 • ACR Convergence 2020
IL-23 Skin and Joint Profiling in Psoriatic Arthritis: Novel Perspectives in Understanding Clinical Responses to IL-23 Inhibitors
Background/Purpose: PsA is a chronic heterogeneous inflammatory condition affecting up to 30% of patients with skin and/or nail psoriasis and the IL-23/IL-17 axis is believed…Abstract Number: 1397 • ACR Convergence 2020
Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort
Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…Abstract Number: 1610 • ACR Convergence 2020
Cutaneous Side Effects of Hydroxychloroquine in Rheumatic Diseases –Combination of “Traditional” Multivariate Analysis for Risk Factors AndClassification Model Development Using Supervised Machine Learning –Single Centre Retrospective Cohort Study in India
Background/Purpose: Hydroxychloroquine (HCQ) is associated with varied cutaneous side effects but only few studies in literature characterizing the risk factors for this. Recently machine learning…Abstract Number: 0076 • ACR Convergence 2020
The Role of Interferon Kappa in Psoriasis
Background/Purpose: Psoriasis is a common, chronic inflammatory autoimmune skin diseases characterized by hyperproliferation and abnormal differentiation of keratinocytes and infiltration of inflammatory cells. Early infiltration…Abstract Number: 1631 • ACR Convergence 2020
No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program
Background/Purpose: Tildrakizumab (TIL) is a high‐affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate to severe plaque psoriasis. We evaluated adverse…Abstract Number: 0263 • ACR Convergence 2020
Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a photosensitive skin disorder that can occur with systemic lupus erythematosus. As CLE often fluctuates in disease activity, little…Abstract Number: 1802 • ACR Convergence 2020
Vitamin D Level: Predictor of SLE Disease Activity in AA Cohort with CLE?
Background/Purpose: There are few predominant African American (AA) epidemiological studies in Cutaneous Lupus Erythematosus (CLE). The Gilliam classification divides CLE into lupus specific, acute cutaneous…Abstract Number: 0283 • ACR Convergence 2020
Genome-wide DNA Methylation Analysis in Lupus Keratinocytes Identifies Differential Methylation of Genes That Regulate Apoptosis
Background/Purpose: Cutaneous lupus erythematous (CLE) is a disfiguring manifestation of systemic LE (SLE), and the pathogenesis remains unclear. However, epidermal regulation of skin inflammation and…Abstract Number: 1906 • ACR Convergence 2020
Hsp90 Inhibition Effectively Prevents Progression of Dermal Fibrosis and Induces Regression of Established Bleomycin-Induced Dermal Fibrosis
Background/Purpose: Our previous study demonstrated that Heat shock protein 90 (Hsp90) is overexpressed in the skin of patients with systemic sclerosis (SSc), in cultured SSc…Abstract Number: 0284 • ACR Convergence 2020
Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-induced Lupus Model
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease in which type I interferons (IFN) play a key role. The IFN response can…
ACR Meeting Abstracts